| Authors: |
Mina R; Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University, 1365 Clifton Rd N E, Atlanta, GA, 30322, USA. rmina2@emory.edu.; The Myeloma Unit, Division of Hematology, University of Turin and Azienda Ospedaliero-Universitaria (AOU) Città della Salute e della Scienza di Torino, Turin, Italy. rmina2@emory.edu., Mylin AK; Department of Hematology, Rigshospitalet, Copenhagen, Denmark., Yokoyama H; Tohoku University Graduate School of Medicine, Sendai, Japan., Magen H; Ramat-Gan, Faculty of Medicine, Tel Aviv University, Tel-Aviv, Israel., Alsdorf W; University Medical Center Hamburg-Eppendorf, Hamburg, Germany., Shune L; The University of Kansas Medical Center, Kansas City, KS, USA., Isufi I; Department of Internal Medicine, Yale School of Medicine, Yale University, New Haven, CT, USA., Harrison SJ; Clinical Haematology, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, Australia.; Sir Peter MacCallum Dep of Oncology, University of Melbourne, Parkville, Australia., Shah UA; Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY, USA., De Champlain A; Johnson & Johnson, Horsham, PA, USA., Katz EG; Johnson & Johnson, Raritan, NJ, USA., Gries KS; Johnson & Johnson, Raritan, NJ, USA., Schecter JM; Johnson & Johnson, Raritan, NJ, USA., Lendvai N; Johnson & Johnson, Raritan, NJ, USA., Slaughter A; Cilag GmbH International, Zug, Switzerland., Lonardi C; Johnson & Johnson, Buenos Aires, Argentina., Deraedt W; Johnson & Johnson, Beerse, Belgium., Costa Filho O; Legend Biotech USA Inc., Somerset, NJ, USA., Patel N; Legend Biotech USA Inc., Somerset, NJ, USA., Florendo E; Legend Biotech USA Inc., Somerset, NJ, USA., Ho KF; STAT-TU Inc, Elora, ON, Canada., Karlin L; Centre Hospitalier Lyon Sud, Pierre- Bénite, France., Weisel K; University Medical Center Hamburg-Eppendorf, Hamburg, Germany. |
